X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pan-trk (32) 32
index medicus (24) 24
alk inhibitor (17) 17
entrectinib (17) 17
oncology (17) 17
humans (14) 14
ros1 (14) 14
pharmacology & pharmacy (12) 12
cancer (11) 11
expression (10) 10
pathology (10) 10
tumors (10) 10
advanced solid tumors (9) 9
etv6-ntrk3 gene fusion (9) 9
oral pan-trk (9) 9
rearrangements (9) 9
acquired-resistance (8) 8
open-label (8) 8
targeted therapy (8) 8
anaplastic lymphoma kinase (7) 7
animals (7) 7
antitumor-activity (7) 7
carcinoma (7) 7
lung cancer (7) 7
nsclc (7) 7
alk (6) 6
inhibitor entrectinib (6) 6
nerve growth-factor (6) 6
potent (6) 6
cell lung-cancer (5) 5
chemistry, medicinal (5) 5
crizotinib (5) 5
fibrosarcoma (5) 5
gene fusion (5) 5
immunohistochemistry (5) 5
immunotherapy (5) 5
infantile fibrosarcoma (5) 5
lung neoplasms - drug therapy (5) 5
mutation (5) 5
ntrk (5) 5
ntrk1 (5) 5
proteins (5) 5
sarcoma (5) 5
trka (5) 5
tyrosine (5) 5
analog secretory carcinoma (4) 4
chemotherapy (4) 4
egfr (4) 4
fusion (4) 4
gene rearrangement (4) 4
genetic aspects (4) 4
identification (4) 4
kinases (4) 4
metastasis (4) 4
non-small cell lung cancer (4) 4
ntrk3 (4) 4
phase-i (4) 4
protein kinase inhibitors - therapeutic use (4) 4
receptor protein-tyrosine kinases - antagonists & inhibitors (4) 4
receptor, trka - antagonists & inhibitors (4) 4
receptor, trkb - antagonists & inhibitors (4) 4
receptor, trkc - antagonists & inhibitors (4) 4
single-arm (4) 4
trkb (4) 4
trkc (4) 4
analysis (3) 3
antineoplastic agents - pharmacology (3) 3
antineoplastic agents - therapeutic use (3) 3
carcinoma, non-small-cell lung - drug therapy (3) 3
care and treatment (3) 3
cell biology (3) 3
ceritinib (3) 3
clinical trials (3) 3
clinical-response (3) 3
colorectal cancer (3) 3
dermatofibrosarcoma protuberans (3) 3
development and progression (3) 3
discovery (3) 3
female (3) 3
gene fusions (3) 3
genes (3) 3
growth-factor receptor (3) 3
health aspects (3) 3
kinase (3) 3
larotrectinib (3) 3
loxo-101 (3) 3
lung neoplasms - genetics (3) 3
male (3) 3
membrane glycoproteins - genetics (3) 3
metastases (3) 3
neoplasms - drug therapy (3) 3
neuroblastoma (3) 3
ntrk1/2/3 (3) 3
ntrk2 (3) 3
oncogene (3) 3
oncogene proteins, fusion - genetics (3) 3
patients (3) 3
pediatrics (3) 3
precision medicine (3) 3
protein kinase inhibitors - pharmacology (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


CLINICAL CANCER RESEARCH, ISSN 1078-0432, 08/2019, Volume 25, Issue 15, pp. 4712 - 4722
Purpose: Targeted next-generation sequencing of DNA has become more widely used in the management of patients with lung adenocarcinoma; however, no clear... 
GENE FUSIONS | IMPACT | PAN-TRK | GENOMICS | SOLID TUMORS | ONCOLOGY | IMMUNOTHERAPY | CLINICAL CHARACTERISTICS | IDENTIFICATION | CANCER | ROS1
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 12/2018, Volume 24, Issue 23, pp. 5807 - 5814
The oncogenesis-promoting role of chromosomal rearrangements for several hematologic and solid malignancies is well recognized. However, identifying... 
RECEPTOR TYROSINE KINASES | PAN-TRK | ONCOLOGY | ANALOG SECRETORY CARCINOMA | ETV6-NTRK3 GENE FUSION | INHIBITOR ENTRECTINIB | ACQUIRED-RESISTANCE | PAPILLARY THYROID-CARCINOMA | ANTITUMOR-ACTIVITY | REARRANGEMENTS | CLINICAL-RESPONSE
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 02/2018, Volume 61, Issue 4, pp. 1737 - 1743
Changes in expression and dysfunctional signaling of TrkA/B/C receptors and oncogenic Trk fusion proteins are found in neurological diseases and cancers. Here,... 
POTENT | ONCOGENE | CHEMISTRY, MEDICINAL | PAN-TRK | ENTRECTINIB | FUSION | RADIOFLUORINATION | ALZHEIMERS-DISEASE | EXPRESSION | CANCER | SCAFFOLD | Pharmacology & Pharmacy
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2017, Volume 35, Issue 23, pp. 2595 - 2597
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 02/2019, Volume 62, Issue 4, pp. 1731 - 1760
The use of kinase-directed precision medicine has been heavily pursued since the discovery and development of imatinib. Annually, it is estimated that around... 
ANAPLASTIC LYMPHOMA KINASE | SIGNAL-TRANSDUCTION PATHWAYS | CHEMISTRY, MEDICINAL | PAN-TRK | TYROSINE KINASE | PROTEIN-KINASE | NEUROTROPHIC FACTOR | PHOSPHATIDYLINOSITOL 3-KINASE | ETV6-NTRK3 GENE FUSION | NERVE GROWTH-FACTOR | SMALL-MOLECULE INHIBITOR
Journal Article
CANCER RESEARCH, ISSN 0008-5472, 07/2019, Volume 79, Issue 13, pp. 3163 - 3168
Oncogenic fusions involving NTRK1, NTRK2, and NTRK3 with various partners are diagnostic of infantile fibrosarcoma and secretory carcinoma yet also occur in... 
PAN-TRK | ONCOLOGY | ANALOG SECRETORY CARCINOMA | ETV6-NTRK3 GENE FUSION | INHIBITOR ENTRECTINIB | ANCHORED MULTIPLEX | ACQUIRED-RESISTANCE | IDENTIFICATION | CLINICAL-RESPONSE | EXPRESSION | MOLECULAR ANALYSIS
Journal Article
Drugs, ISSN 0012-6667, 9/2019, Volume 79, Issue 13, pp. 1477 - 1483
Entrectinib (Rozlytrek ® ) is an oral selective inhibitor of the tyrosine kinases tropomyosin receptor kinases (Trk)A/B/C [encoded by the genes neurotrophic... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | PAN-TRK | EFFICACY | SAFETY | PHARMACOLOGY & PHARMACY | TOXICOLOGY | NTRK | ALK INHIBITOR | ANTITUMOR-ACTIVITY | ROS1 | TUMORS
Journal Article
The American Journal of Surgical Pathology, ISSN 0147-5185, 04/2019, Volume 43, Issue 4, pp. 435 - 445
Pediatric mesenchymal tumors harboring variant NTRK fusions (ETV6-negative) are being increasingly described; however, the histologic and clinical features of... 
NTRK | soft tissue sarcoma | TRK | infantile fibrosarcoma | pediatric | ALK | SURGERY | LAROTRECTINIB | PAN-TRK | MANAGEMENT | TISSUE | CONGENITAL MESOBLASTIC NEPHROMA | PATHOLOGY | SUBSET | CHILDREN | ETV6-NTRK3 GENE FUSION | Tumors in children | Development and progression | Genetic aspects | Sarcoma | Health aspects | Gene fusion
Journal Article
Modern Pathology, ISSN 0893-3952, 01/2019, Volume 32, Issue 1, pp. 147 - 153
Targeted inhibitors of neurotropic tyrosine kinases are highly effective in selected patients with gene fusions involving NTRK1, NTRK2, or NTRK3. These fusions... 
PAN-TRK | ENTRECTINIB | INFANTILE FIBROSARCOMA | PATIENT | PATHOLOGY | ALK INHIBITOR | REARRANGEMENTS | CLINICAL-RESPONSE | ROS1 | CARCINOMA | IMMUNOHISTOCHEMISTRY | Tyrosine | Immunohistochemistry | Genes | Fibrosarcoma | Microsatellite instability | Gene fusion | Thyroid carcinoma | Breast carcinoma | Immune checkpoint | Colon cancer | Glioma | Nose | PD-L1 protein | TrkA protein | TrkA receptors | Colon | Cervical cancer | Movement disorders | Thyroid
Journal Article
Annals of Oncology, ISSN 0923-7534, 09/2019, Volume 30, Issue 9, pp. 1417 - 1427
Abstract Background NTRK1, NTRK2 and NTRK3 fusions are present in a plethora of malignancies across different histologies. These fusions represent the most... 
NTRK1 | NTRK2 | PAN-TRK | next-generation sequencing | NTRK3 | INHIBITOR ENTRECTINIB | ACQUIRED-RESISTANCE | fluorescence in situ hybridisation | PROTEIN-TYROSINE KINASE | CANCER | MESOBLASTIC NEPHROMA | ONCOLOGY | ANALOG SECRETORY CARCINOMA | ETV6-NTRK3 GENE FUSION | immunohistochemistry | MUTATIONS | EXPRESSION
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 09/2018, Volume 13, Issue 9, pp. 1373 - 1382
-rearranged NSCLC is classified as a distinct molecular subset of NSCLC with a therapeutic target. rearrangement is most often identified in never-smokers with... 
Crizotinib | Non–small cell lung cancer | Carcinoma | ROS1 | Pemetrexed | PLUS CISPLATIN | ROS1 REARRANGEMENT | PAN-TRK | GENE REARRANGEMENTS | THYMIDYLATE SYNTHASE EXPRESSION | ALK INHIBITOR | TRIAL | THERAPY | ONCOLOGY | RESPIRATORY SYSTEM | Non-small cell lung cancer | PEMETREXED-BASED CHEMOTHERAPY
Journal Article
Journal of Drug Targeting, ISSN 1061-186X, 04/2019, Volume 27, Issue 4, pp. 442 - 450
Collective data suggest tropomyosin-related kinase B (TrkB), which is correlated with the growth, migration and poor prognosis of neuroblastoma (NB), is a... 
neuroblastoma | BDNF | Tropomyosin receptor kinase B | GZD2202 | CELLS | PAN-TRK | ALK INHIBITOR | NGF | DISCOVERY | NERVE GROWTH-FACTOR | POTENT | ENTRECTINIB | PHARMACOLOGY & PHARMACY | ROS1 | EXPRESSION
Journal Article
Medical Oncology, ISSN 1357-0560, 06/2017, Volume 34, Issue 6, p. 1
In the era of personalized medicine, the identification of targetable genetic alterations represented a major step forward in anticancer therapy. NTRK... 
LOXO-101 | Entrectinib | NTRK mutations | NSCLC | ADVANCED SOLID TUMORS | ORAL PAN-TRK | ADENOCARCINOMA | RECEPTOR | OPEN-LABEL | CHEMOTHERAPY | EGFR | ONCOLOGY | ALK-INHIBITOR | EXPRESSION | Pharmaceutical industry | Lung cancer
Journal Article
Bioorganic & Medicinal Chemistry Letters, ISSN 0960-894X, 08/2019, Volume 29, Issue 16, pp. 2320 - 2326
The design, synthesis, and biological evaluation of novel 3-aryl-indazole derivatives as peripherally selective pan-Trk inhibitors are described. Three... 
pan-Trk inhibitor | pKa-MB | 3-Aryl-indazole derivative | Peripherally restricted | Efflux transporter | CHEMISTRY, MEDICINAL | CHEMISTRY, ORGANIC | ANTAGONISM | Plasma physics | Care and treatment | Pain | Analysis | Nerve growth factor | Permeability | Muscle proteins | Derivatives (Financial instruments) | Adenosine triphosphate
Journal Article
Histopathology, ISSN 0309-0167, 07/2019, Volume 75, Issue 1, pp. 54 - 62
Aims Secretory carcinoma (previously known as mammary analogue secretory carcinoma) is characterised by ETV6 rearrangements, most often ETV6–NTRK3 fusion.... 
pan‐TRK | acinic cell carcinoma | immunohistochemistry | NTRK | secretory carcinoma | pan-TRK | DIAGNOSIS | TRANSLOCATION | MARKER | PATHOLOGY | THYROID-GLAND | REARRANGEMENTS | SUBSET | TUMORS | CELL BIOLOGY | ETV6-NTRK3 GENE FUSION | MAMMAGLOBIN | Immunohistochemistry | Monoclonal antibodies | Carcinoma | Cancer | Salivary gland | Hybridization | Tumors | Metastases
Journal Article
The American Journal of Surgical Pathology, ISSN 0147-5185, 05/2018, Volume 42, Issue 10, pp. 1275 - 1285
Journal Article
Clinical Lung Cancer, ISSN 1525-7304, 05/2019, Volume 20, Issue 3, pp. e233 - e237
Journal Article